Xenon Pharmaceuticals Inc.
Total Trades
35
Buys
1
Sells
20
Largest Trade
$1M+
Insiders
9
Institutional Funds
186
Inst. Value
$1M+
Activist Filings
18
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO | SELL | $1M+ | 40K | $44.43 | Jan 2, 2026 |
| MORTIMER IAN | PRESIDENT & CEO | EXERCISE | $100K–$500K | 40K | $7.49 | Jan 2, 2026 |
| MORTIMER IAN | PRESIDENT & CEO | SELL | $1M+ | 25K | $45.33 | Dec 10, 2025 |
| MORTIMER IAN | PRESIDENT & CEO | SELL | $1K–$15K | 97 | $45.01 | Dec 4, 2025 |
| MORTIMER IAN | PRESIDENT | EXERCISE | $100K–$500K | 25K | $7.69 | Oct 1, 2025 |
| MORTIMER IAN | PRESIDENT | SELL | $1M+ | 25K | $40.16 | Oct 1, 2025 |
| GANNON STEVEN | Director | SELL | <$1K | 3 | $30.48 | Jun 6, 2025 |
| MORTIMER IAN | PRESIDENT & CEO | SELL | $1M+ | 55K | $40.25 | Jan 28, 2025 |
| MORTIMER IAN | PRESIDENT & CEO | EXERCISE | $500K+ | 55K | $17.76 | Jan 28, 2025 |
| PATOU GARY | Director | EXERCISE | $50K–$100K | 7K | $10.24 | Nov 23, 2024 |
| PATOU GARY | Director | SELL | $100K–$500K | 5K | $41.09 | Nov 23, 2024 |
| Svoronos Dawn | Director | SELL | $500K+ | 25K | $38.70 | Aug 24, 2023 |
| PIMSTONE SIMON N. | Director | SELL | $1M+ | 131K | $38.90 | Jun 1, 2023 |
| PIMSTONE SIMON N. | Director | EXERCISE | $1M+ | 134K | $15.30 | Jun 1, 2023 |
| MORTIMER IAN | PRESIDENT & CEO | EXERCISE | $500K+ | 69K | $9.60 | May 26, 2023 |
| MORTIMER IAN | PRESIDENT & CEO | SELL | $1M+ | 32K | $41.41 | May 26, 2023 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Offi… | SELL | $15K–$50K | 700 | $35.01 | Mar 24, 2023 |
| PIMSTONE SIMON N. | Director | EXERCISE | $100K–$500K | 72K | $2.64 | Mar 9, 2023 |
| PIMSTONE SIMON N. | Director | SELL | $500K+ | 19K | $36.98 | Mar 9, 2023 |
| PATOU GARY | Director | EXERCISE | $1K–$15K | 2K | $2.68 | Nov 29, 2022 |
| PATOU GARY | Director | SELL | $100K–$500K | 4K | $34.55 | Nov 29, 2022 |
| AULIN SHERRY | CFO | EXERCISE | $100K–$500K | 19K | $6.97 | Sep 7, 2022 |
| AULIN SHERRY | CFO | SELL | $500K+ | 15K | $39.57 | Sep 7, 2022 |
| ROBIN SHERRINGTON | EVP | SELL | $1M+ | 65K | $38.31 | Sep 2, 2022 |
| ROBIN SHERRINGTON | EVP | EXERCISE | $100K–$500K | 72K | $4.25 | Sep 2, 2022 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | SELL | $1M+ | 58K | $38.31 | Aug 16, 2022 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | EXERCISE | $100K–$500K | 65K | $4.24 | Aug 16, 2022 |
| PIMSTONE SIMON N. | Director | SELL | $1M+ | 177K | $38.25 | Aug 16, 2022 |
| PIMSTONE SIMON N. | Director | SELL | $1M+ | 55K | $29.28 | Mar 9, 2022 |
| PIMSTONE SIMON N. | Director | EXERCISE | $100K–$500K | 31K | $3.67 | Mar 9, 2022 |
| ROBIN SHERRINGTON | EVP | SELL | $500K+ | 22K | $30.50 | Mar 9, 2022 |
| ROBIN SHERRINGTON | EVP | EXERCISE | $15K–$50K | 7K | $3.67 | Mar 9, 2022 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | SELL | $1M+ | 51K | $30.63 | Mar 9, 2022 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | EXERCISE | $500K+ | 68K | $7.43 | Mar 9, 2022 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Offi… | BUY | $15K–$50K | 700 | $28.81 | Jan 21, 2022 |
Institutional Ownership
13F filings as of Dec 31, 2025 · 186 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| Capital International Investors | 3.4M | $1M+ | SH |
| BRAIDWELL LP | 1.8M | $1M+ | SH |
| ALLIANCEBERNSTEIN L.P. | 1.6M | $1M+ | SH |
| STATE STREET CORP | 1.5M | $1M+ | SH |
| JENNISON ASSOCIATES LLC | 1.3M | $1M+ | SH |
| Affinity Asset Advisors, LLC | 1.3M | $1M+ | SH |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.2M | $1M+ | SH |
| GEODE CAPITAL MANAGEMENT, LLC | 868K | $1M+ | SH |
| Siren, L.L.C. | 813K | $1M+ | SH |
| First Turn Management, LLC | 800K | $1M+ | SH |
| Aberdeen Group plc | 750K | $1M+ | SH |
| AMERICAN CENTURY COMPANIES INC | 680K | $1M+ | SH |
| FEDERATED HERMES, INC. | 672K | $1M+ | SH |
| Capital World Investors | 656K | $1M+ | SH |
| Pictet Asset Management Holding SA | 626K | $1M+ | SH |
| Trails Edge Capital Partners, LP | 597K | $1M+ | SH |
| Caligan Partners LP | 550K | $1M+ | SH |
| BARCLAYS PLC | 542K | $1M+ | SH |
| TimesSquare Capital Management, LLC | 533K | $1M+ | SH |
| LOOMIS SAYLES & CO L P | 500K | $1M+ | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
Wellington Management Group LLP
SC 13G · Feb 10, 2026
6.2%
4.8M shares
SC 13G · Nov 14, 2025
5.1%
3.9M shares
Wellington Management Group LLP
SC 13G/A · Aug 12, 2025
2.8%
2.2M shares
SC 13G/A · Aug 6, 2025
11.5%
8.8M shares
SC 13G · Jul 17, 2025
6.2%
4.8M shares
SC 13G/A · Mar 7, 2025
10.3%
7.9M shares
SC 13G/A · Nov 12, 2024
9.1%
6.9M shares
SC 13G/A · Feb 14, 2024
7.7%
5.7M shares
DRIEHAUS CAPITAL MANAGEMENT LLC
SC 13G/A · Feb 14, 2024
5.9%
4.3M shares
SC 13G/A · Feb 14, 2023
7.8%
4.9M shares
Biotechnology Value Fund, L.P.
SC 13G/A · Feb 14, 2023
1.1%
681K shares
DRIEHAUS CAPITAL MANAGEMENT LLC
SC 13G/A · Feb 10, 2023
7.5%
4.7M shares
SC 13G/A · Feb 9, 2023
7.5%
4.7M shares
Biotechnology Value Fund, L.P.
SC 13G/A · Mar 18, 2022
4.4%
2.3M shares
Biotechnology Value Fund, L.P.
SC 13G/A · Feb 14, 2022
5.5%
2.8M shares
DRIEHAUS CAPITAL MANAGEMENT LLC
SC 13G · Feb 14, 2022
6.0%
3.1M shares
SC 13G/A · Feb 11, 2022
1.2%
631K shares
SC 13G/A · Feb 11, 2022
9.7%
5.0M shares